Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Almirall, S.A.

EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology
From Almirall, S.A.
Via Business Wire
Almirall H1 2025 Results
From Almirall, S.A.
Via Business Wire
Almirall Q1 2025 Results
From Almirall, S.A.
Via Business Wire
AAD 2025: Almirall presents early-stage pipeline progress and real-world evidence on demonstrating AK treatment success and patient satisfaction with Tirbanibulin
From Almirall, S.A.
Via Business Wire
Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline
From Almirall, S.A.
Via Business Wire
Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth
From Almirall, S.A.
Via Business Wire
Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe
From Almirall, S.A.
Via Business Wire
Almirall’s H1 2024 Results: Almirall Delivers Strong Performance in the First Half of 2024, Achieving Net Sales Growth of 6.7% Driven by Its European Dermatology Business and Accelerating Biologics Sales
From Almirall, S.A.
Via Business Wire
Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio
From Almirall, S.A.
Via Business Wire
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
From Almirall, S.A.
Via Business Wire
Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business
From Almirall, S.A.
Via Business Wire
Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology
From Almirall, S.A.
Via Business Wire
Almirall’s First Quarter 2023 Results
From Almirall, S.A.
Via Business Wire
Almirall’s Full-Year 2022 Results
From Almirall, S.A.
Via Business Wire
Almirall’s Nine-month 2022 Results
From Almirall, S.A.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.